Ernexa Therapeutics (ERNA) announced that new data will be presented at the American Society of Clinical Oncology Annual Meeting 2025 on June 2 in Chicago. The study explored the technology behind Ernexa’s novel iMSC-based immunotherapy platform, which uses induced mesenchymal stem cells engineered to secrete cytokines IL-7 and IL-15 directly into ovarian tumors. These iMSCs, derived from adult skin cells, safely migrated into the tumor microenvironment and triggered strong immune activation, including T cell and macrophage infiltration, turning immunologically “cold” tumors into “hot” ones.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERNA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue